Teva to cease US shipments of generic Ortho Tri-Cyclen
This article was originally published in Scrip
Executive Summary
Teva Pharmaceutical Industries has agreed to cease US shipments of its generic version of Johnson & Johnson's Ortho Tri-Cyclen Lo (norgestimate plus ethinylestradiol), pending a preliminary injunction hearing in a related patent infringement case scheduled to begin on July 15th. The move follows a July 1st "at risk" launch of the generic product by Teva after it had gained FDA final approval of its ANDA.